Sulindac Exhibits Anti-proliferative and Anti-invasive Effects in Uterine Serous Carcinoma Cells

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2024 Aug 28

PMID 39198302

Authors

Shuning Chen

Weimin Kong

Xiaochang Shen

Boer Deng

Jennifer Haag

Nikita Sinha

Catherine John

Wenchuan Sun

Chunxiao Zhou

Victoria L Bae-Jump

Affiliations

Soon will be listed here.

Abstract

Purpose: Uterine serous carcinoma (USC) is a highly aggressive and frequently recurring subtype of endometrial cancer with limited treatment options for advanced or recurrent stages. Sulindac, a classic non-steroidal anti-inflammatory drug, has demonstrated anti-tumor activity in several pre-clinical tumor models. This study aims to evaluate the effect of sulindac on cell proliferation and invasion in USC cells.

Methods: Human USC cell lines ARK-1 and SPEC2 were treated with different concentrations of sulindac. Cell proliferation was assessed using MTT and colony formation assays. ELISA assays measured cellular stress, cleaved caspase 3 activity, antioxidant ability, and adhesion. Cell cycle arrest was evaluated by Cellometer. The invasive capability was detected by wound healing assay. Western blotting was used to analyze the changes in protein expression induced by sulindac.

Results: Exposure to sulindac decreased cellular viability in a dose-dependent manner in ARK-1 and SPEC2 cells. Sulindac effectively inhibited cell cycle progression, increased cellular stress, caused apoptosis, and reduced cell adhesion and invasion in USC cells. Additionally, sulindac decreased the expression of COX-2 and blocked phosphorylation of NF-κB induced by TNF-α.

Conclusion: Sulindac is a potential therapeutic agent for USC that deserves further exploration in pre-clinical studies and potentially future clinical trials.

References

Bogani G, Ray-Coquard I, Concin N, Ngoi N, Morice P, Enomoto T . Uterine serous carcinoma. Gynecol Oncol. 2021; 162(1):226-234. PMC: 9445918. DOI: 10.1016/j.ygyno.2021.04.029. View

Sun Y, Tang X, Half E, Kuo M, Sinicrope F . Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 2002; 62(21):6323-8. View

Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M . The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol. 2010; 2010:215158. PMC: 2841246. DOI: 10.1155/2010/215158. View

Ko C, Lan S, Lu Y, Cheng T, Lai P, Tsai C . Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis. Oncogene. 2017; 36(32):4597-4609. DOI: 10.1038/onc.2017.82. View

Borneman R, Gavin E, Musiyenko A, Richter W, Lee K, Crossman D . Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer. J Ovarian Res. 2022; 15(1):120. PMC: 9632086. DOI: 10.1186/s13048-022-01050-9. View

Karl T, Seibert N, Stohr M, Osswald H, Rosl F, Finzer P . Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2006; 245(1-2):103-11. DOI: 10.1016/j.canlet.2005.12.034. View

Kim H, Kim E, Yang S, Jeong E, Park C, Kim S . Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction. Int J Oncol. 2006; 28(6):1401-8. View

Toyoshima T, Kamijo R, Takizawa K, Sumitani K, Ito D, Nagumo M . Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21. Br J Cancer. 2002; 86(7):1150-6. PMC: 2364196. DOI: 10.1038/sj.bjc.6600183. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

10.

Takiuchi T, Blake E, Matsuo K, Sood A, Brasky T . Aspirin use and endometrial cancer risk and survival. Gynecol Oncol. 2017; 148(1):222-232. PMC: 7531033. DOI: 10.1016/j.ygyno.2017.10.026. View

11.

Vaish V, Rana C, Piplani H, Vaiphei K, Sanyal S . Sulindac and Celecoxib regulate cell cycle progression by p53/p21 up regulation to induce apoptosis during initial stages of experimental colorectal cancer. Cell Biochem Biophys. 2013; 68(2):301-19. DOI: 10.1007/s12013-013-9711-8. View

12.

Sui H, Zhou Y, Wang H, Li L, Cao M, Huang J . Effects of sulindac sulfide on proliferation and apoptosis of human breast cancer cell. Oncol Lett. 2018; 15(5):7981-7986. PMC: 5962841. DOI: 10.3892/ol.2018.8331. View

13.

Hamilton C, Cheung M, Osann K, Chen L, Teng N, Longacre T . Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006; 94(5):642-6. PMC: 2361201. DOI: 10.1038/sj.bjc.6603012. View

14.

Zhao H, Yi B, Liang Z, Phillips C, Lin H, Riker A . Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer. Genes Dis. 2021; 8(3):320-330. PMC: 8093647. DOI: 10.1016/j.gendis.2020.11.006. View

15.

Boolbol S, Dannenberg A, Chadburn A, Martucci C, Guo X, Ramonetti J . Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996; 56(11):2556-60. View

16.

Kim Y, Seol C, Jung J, Oh S, Hwang K, Kim H . Synergistic Effect of Sulindac and Simvastatin on Apoptosis in Lung Cancer A549 Cells through AKT-Dependent Downregulation of Survivin. Cancer Res Treat. 2014; 47(1):90-100. PMC: 4296852. DOI: 10.4143/crt.2013.194. View

17.

Li N, Xi Y, Tinsley H, Gurpinar E, Gary B, Zhu B . Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. Mol Cancer Ther. 2013; 12(9):1848-59. PMC: 3800150. DOI: 10.1158/1535-7163.MCT-13-0048. View

18.

Hwang K, Park C, Kwon S, Kim Y, Park D, Lee M . Synergistic induction of apoptosis by sulindac and simvastatin in A549 human lung cancer cells via reactive oxygen species-dependent mitochondrial dysfunction. Int J Oncol. 2013; 43(1):262-70. DOI: 10.3892/ijo.2013.1933. View

19.

Konjalwar S, Ceyhan B, Rivera O, Nategh P, Neghabi M, Pavlovic M . Demonstrating drug treatment efficacies by monitoring superoxide dynamics in human lung cancer cells with time-lapse fluorescence microscopy. J Biophotonics. 2023; 17(2):e202300331. DOI: 10.1002/jbio.202300331. View

20.

Vaish V, Sanyal S . Role of Sulindac and Celecoxib in the regulation of angiogenesis during the early neoplasm of colon: exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/β-catenin signaling. Biomed Pharmacother. 2012; 66(5):354-67. DOI: 10.1016/j.biopha.2012.01.004. View